A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A phase 3 trial of Abiraterone acetate and Prednisone in Prostate cancer, run by Janssen Research & Development, LLC, completed.
Overview
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate is a phase 3 interventional study registered as NCT01517802 by Janssen Research & Development, LLC, with 32 participants recorded, started 2012-03-28 and reaching its primary completion in 2021-04-22. Interventions recorded: Abiraterone acetate, Prednisone. Conditions recorded: Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer.
Linked to the idea "Prescribe a quarter dose of abiraterone with breakfast" because the registry names Abiraterone acetate and Prednisone among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialConventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Shares Prescribe a quarter dose of abiraterone with breakfast, Prednisone, Abiraterone acetate, Prostate cancer and the tag pipeline.
- TrialA Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Shares Prednisone, Abiraterone acetate, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Prednisone, Abiraterone acetate, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialStudy of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Shares Prednisone, Abiraterone acetate, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialPharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Shares Abiraterone acetate, Prostate cancer and the tag pipeline.
- TrialA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Shares Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Shares Prednisone, Prostate cancer and the tag pipeline.